- Epitalon's aging and telomerase claims rest largely on work from a single research group, with no rigorous independent human trials and no female-specific data indexed.
- Human trials of NAD-boosting compounds have enrolled women, yet across the indexed literature few studies reported outcomes by sex, so the female picture stays inferred rather than measured.
- MOTS-c is a rare case where some rodent work reported sex differences, an unusually high share for this field, though no controlled human female data exists.
The longevity corner of peptide research is where the gap between what is claimed and what is measured grows widest. Compounds here are marketed against aging itself, one of the hardest endpoints in biology to study, and the human data behind the headline claims is often thin, unreplicated, or absent. This page maps four of the most-discussed aging-research materials, epitalon, NAD+, MOTS-c, and humanin, against what the literature actually supports, and against the question this site was built to ask: how many of the underlying studies included women at all.
Epitalon: bold claims, thin evidence
Epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, modeled on epithalamin, a preparation originally derived from pineal-gland extract. In laboratory systems it has been studied for proposed influence on telomerase activity, telomere dynamics, and circadian gene expression. The catch is that much of this work traces back to a limited number of research groups, and the underlying mechanisms are not well characterized in rigorous, independently replicated models. It is best understood as an exploratory research material, not an established one.
On the female-evidence axis, epitalon is a study in blanks. There is no menstrual-cycle interaction data, no pregnancy or lactation safety data, and no menopause-specific data, despite the pineal and aging framing that might seem to invite it. Absence of harm data is not evidence of safety; it is simply absence.
NAD+: real biology, unstratified data
NAD+, nicotinamide adenine dinucleotide, sits on far firmer mechanistic ground. It is an essential coenzyme present in all living cells, central to redox reactions, mitochondrial electron transport, and the activity of sirtuin and PARP enzymes tied to DNA repair and gene regulation. Its role in metabolism is textbook; what remains uncertain is what supplementing NAD-boosting compounds does at the level of human aging outcomes.
Here the female story is more nuanced than a blank. Human trials of NAD-boosting compounds have enrolled women, and aging-research cohorts routinely include women in the perimenopausal and menopausal age range. The problem is analysis, not enrollment: across the indexed literature, many studies included women but few reported sex-stratified outcomes, and menopausal status is rarely broken out. The result is a body of evidence that is extrapolated to women more than it is measured in them.
Mitochondrial-derived peptides: MOTS-c and humanin
MOTS-c and humanin belong to an unusual class: peptides encoded within mitochondrial DNA rather than the nuclear genome. MOTS-c, a 16-residue sequence, has been studied in preclinical systems for activation of the AMPK energy-sensing pathway and its influence on glucose and lipid metabolism. Humanin, a smaller mitochondrial-derived peptide, has been studied for cytoprotective signaling and metabolic pathways relevant to cellular aging.
MOTS-c is worth singling out. In the indexed literature, some studies used female animals and a smaller number reported sex differences in rodents, an unusually high share for this database, where sex-blind design is the norm. Some rodent work also suggests estrogen may modulate mitochondrial-peptide effects. None of this is characterized in humans, and no controlled human female data exists, so the honest read is that MOTS-c shows where the field could go, not where it has arrived.
Where the research literature reports dose ranges, it does so for laboratory and preclinical contexts only. None of these compounds has an established, consensus human dose, and this site does not publish personal dosing, protocols, or medical advice.
Read across all four, the longevity category illustrates the core problem this site tracks: mechanistic enthusiasm outruns human evidence, and human evidence, where it exists, is rarely stratified by sex. NAD+ has genuine biology and enrolled women without analyzing them separately; MOTS-c hints at sex differences no human study has confirmed; epitalon and humanin sit largely in the preclinical and anecdotal range. For the full per-compound breakdown of what was studied in women and what was not, see the epitalon, NAD+, MOTS-c, and humanin profiles.